Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543135 | 0.98 | MEN1 (0.31) | — | |
| SCHEMBL31549543 | 0.98 | MEN1 (0.31) | — | |
| SCHEMBL23919231 | 0.98 | MEN1 (0.31) | — | |
| SCHEMBL10374187 | 0.96 | MEN1 (0.31) | SMN1; SMN2 | |
| SCHEMBL23349923 | 0.86 | PHGDH (0.34) | SMN1; SMN2 | |
| SCHEMBL19341401 | 0.85 | OPRD1 (0.32) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL22191150 | 0.79 | — | — | |
| Acetic Acid SCHEMBL28367890 | 0.79 | OPRD1 (0.32) | — | |
| SCHEMBL6013953 | 0.79 | — | — | |
| SCHEMBL21753956 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3677574-B1 | GADOBUTROL PRODUCTION METHOD USING A NANOFILTRATION PURIFICATION STEP | ENZYCHEM LIFESCIENCES CORP (KR) | 2023-10-11 | — | — | EP | disclosed |
| US-20210276961-A1 | METHOD FOR MANUFACTURING CALCOBUTROL | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2021-09-09 | — | — | US | disclosed |
| EP-3875453-A1 | METHOD FOR MANUFACTURING CALCOBUTROL | Enzychem Lifesciences Corporation (KR) | 2021-09-08 | — | — | EP | disclosed |
| CN-113354594-A | Method for preparing combretastatin calcium | 株式会社Enzychem生命科学 | 2021-09-07 | — | — | CN | disclosed |
| US-11091449-B2 | Gadobutrol intermediate and gadobutrol production method using same | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2021-08-17 | — | — | US | disclosed |
| EP-3677574-A1 | GADOBUTROL INTERMEDIATE AND GADOBUTROL PRODUCTION METHOD USING SAME | Enzychem Lifesciences Corporation (KR) | 2020-07-08 | — | — | EP | disclosed |
| US-20200181098-A1 | GADOBUTROL INTERMEDIATE AND GADOBUTROL PRODUCTION METHOD USING SAME | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2020-06-11 | — | — | US | disclosed |
| CN-111065629-A | Gadobutrol intermediate and production method of addol using gadobutrol intermediate | 株式会社Enzychem生命科学 | 2020-04-24 | — | — | CN | disclosed |
| WO-2020040617-A1 | METHOD OF MANUFACTURING GADOBUTROL | 에스티팜 주식회사 | 2020-02-27 | — | — | WO | disclosed |
| EP-0512901-B1 | Aminated polycyclic compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-06-23 | — | — | EP | disclosed |
| WO-1993024469-A1 | PROCESS FOR PRODUCING N-β-HYDROXYALKYL-TRI-N-CARBOXYALKYL-1,4,7,10-TETRAAZACYCLODODECANE AND N-β-HYDROXYALKYL-TRI-N-CARBOXYALKYL-1,4,8,11-TETRAAZACYCLOTETRADECANE DERIVATIVES AND THEIR METAL COMPLEXES | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993018002-A1 | QUATERNARY SALTS OF 4-SUBSTITUTED PIPERIDINES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-09-16 | — | — | WO | disclosed |
| EP-0559538-A1 | Quaternary salts of 4-substituted piperidines, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1993-09-08 | — | — | EP | disclosed |
| EP-0375560-B1 | ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-05-12 | — | — | EP | disclosed |
| EP-0515240-A1 | N-alkylidene piperidine compounds and their enatiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-11-25 | — | — | EP | disclosed |
| EP-0512902-A1 | Dialkyleneperidino compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-11-11 | — | — | EP | disclosed |
| EP-0512901-A1 | Aminated polycyclic compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-11-11 | — | — | EP | disclosed |
| EP-0474561-A1 | Arylalkylamines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-03-11 | — | — | EP | disclosed |
| EP-0428434-A2 | Compounds of aromatic amines and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1991-05-22 | — | — | EP | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091449-B2 | Gadobutrol intermediate and gadobutrol production method using same | GUCY1B2, GUCY1A2, GUCY1B1 | SMN1; SMN2 784/4885 |
| US-20200181098-A1 | GADOBUTROL INTERMEDIATE AND GADOBUTROL PRODUCTION METHOD USING SAME | GUCY1B2, GUCY1A2, GUCY1B1 | SMN1; SMN2 784/4885 |
| US-20210276961-A1 | METHOD FOR MANUFACTURING CALCOBUTROL | CALCB, CALCA, CLIC1 | SMN1; SMN2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.